LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024..

伦敦——（商业新闻短讯）——沉默疗法股份有限公司（纳斯达克：SLN）（“沉默”或“公司”）是一家经验丰富且创新的生物技术公司，致力于通过精密工程药物沉默疾病来改变人们的生活，今天宣布，自2015年以来一直担任沉默公司董事会（“董事会”）独立成员的阿利斯泰尔·格雷通知公司，他将于2024年5月1日退休。。

Iain Ross, Silence’s Chairman of the Board, commented, “Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the development of a new generation of medicines harnessing the body’s natural mechanism of RNA interference, developed a pipeline of innovative product candidates, secured meaningful big pharma partnerships and established a first-class management team.

沉默公司董事会主席伊恩·罗斯（IainRoss）评论道：“过去九年来，阿利斯泰尔为董事会和公司做出了重大贡献。在他担任董事会成员期间，该公司已转型为一家全球性公司，专注于开发利用人体天然RNA干扰机制的新一代药物，开发了一系列创新产品候选产品，建立了有意义的大型制药合作伙伴关系，并建立了一流的管理团队。

I want to recognise and thank Alistair for his input on behalf of the Board and management over almost a decade. We wish him well in the future.'.

我要感谢Alistair在近十年来代表董事会和管理层所做的贡献。我们祝他今后一切顺利。”。

Mr. Gray stated, “Nearly 10 years after joining the Silence Board and at age 75, I feel the time is right to retire as a director. When I joined Silence, there were few targets in the clinic and the organisation was in an early stage of development. Since 2019, we have enjoyed a period of stability under the leadership of Iain Ross, our Chair, and I have been privileged to serve as Senior Independent Director.

格雷先生表示：“在加入沉默董事会近10年后，75岁的时候，我觉得是时候退休了。当我加入沉默时，诊所几乎没有目标，组织处于早期发展阶段。自2019年以来，我们在主席伊恩·罗斯（IainRoss）的领导下保持了一段稳定时期，我有幸担任高级独立董事。

Under the executive leadership of Craig Tooman, our President and Chief Executive Officer, our business has been transformed both clinically and financially to a point where we have a number of product candidates advancing in the clinic and increasing recognition of Silence as a true platform company.

在总裁兼首席执行官克雷格·托曼（CraigTooman）的领导下，我们的业务在临床和财务上都发生了转变，我们有许多产品候选产品在临床上取得了进展，并越来越认识到沉默是一家真正的平台公司。

I would like to thank my colleagues on the Board and the executives as well as our staff in Berlin, London and New Jersey for their support and encouragement over our time together.”.

我要感谢我的董事会同事、高管以及我们在柏林、伦敦和新泽西州的员工，感谢他们在我们共同度过的时光中给予的支持和鼓励。”。

About Silence Therapeutics

关于沉默疗法

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.

沉默疗法（Silence Therapeutics）正在开发新一代药物，利用人体的RNA干扰（RNAi）自然机制来抑制特定靶基因的表达，这些基因被认为在严重未满足需求的疾病的病理学中起作用。沉默公司专有的mRNAi GOLD™平台可用于创建siRNA（短干扰RNA），精确靶向并沉默肝脏中与疾病相关的基因，这是一个巨大的机会。

Silence's wholly owned product candidates include zerlasiran (SLN360) designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and divesiran (SLN124) designed to address rare hematological diseases, including polycythemia vera.

沉默公司的全资候选产品包括zerlasiran（SLN360），旨在解决高脂蛋白（a）出生的人在降低心血管风险方面的高度和普遍未满足的医疗需求，以及Deveriran（SLN124），旨在解决罕见的血液病，包括真性红细胞增多症。

Silence also maintains ongoing research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/..

沉默公司还与阿斯利康和汉索制药等公司保持持续的研发合作。有关更多信息，请访问https://www.silence-therapeutics.com/..